At ProQR science is literally at the heart of what we do. Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments.
… two dosing cohorts and is intended to inform next steps in development. We also plan to provide an update from the … Rare Pediatric Disease designation from the Food and Drug Administration (FDA). Granted access to the PRIority … data from the study are expected in 2021. Received Orphan Drug designation and Fast Track designation from the FDA. …
… of efficacy for the purpose of informing next steps in development and future trial strategy,” said David Rodman, M.D., Executive Vice President of Research and Development of ProQR. “We are pleased with the current safety … injections in the eye and has been granted orphan drug designation in the US and the European Union and …
